MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221. Its pipeline targets a range of disorders including neurodegenerative, inflammatory, fibrotic, metabolic, and respiratory diseases, reflecting a portfolio built around differentiated mechanisms of action and clinical development across multiple indications. The company works through strategic alliances and clinical collaborations to advance its programs and support drug development from early research through later-stage trials. Headquartered in La Jolla, California, MediciNova Inc. occupies a specialized role in the biotechnology market by pursuing therapies for complex conditions where current treatment options remain limited.
Website4275 Executive Square
La Jolla, CA, 92037
United States
MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyceridemia.
Investors talking about MNOV also mention
What share of all stock conversation is about MNOV?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% -0.02 | 0% +0 | 0% +0 | 0% +0 |
Of the messages about MNOV that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 55.46% -18.41 | 66.18% -33.82 | 83.26% -5.79 | ||
| Bearish | — | 44.54% +18.41 | 33.82% +33.82 | 16.74% +5.79 |
Of the messages about MNOV that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 91.3% | 76.56% | 52.2% | ||
| Analysts | — | 8.7% | 7.81% | 12.09% | ||
| Technical Analysis | — | 0% | 15.63% | 28.02% | ||
| Controversies | — | 0% | 0% | 0.55% | ||
| Earnings | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 7.14% |
Of the messages about MNOV, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 37.7% | 43.89% | 33.09% | ||
| Newcomers | — | 62.3% | 56.11% | 66.91% |